Press release
Lassa Fever - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Inovio Pharmaceuticals, Emergent BioSolutions Inc, GeoVax Labs Inc, Globavir Bioscie
Lassa Fever Pipeline Insight
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31234
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is a hemorrhagic virus that can cause bleeding without any symptoms.
Lassa fever virus is a disease that is animal-borne or spread to humans from animals. It is spread to people through contact with household items, food, water, or air contaminated with the droppings or urine of infected multimammate rats (Mastomyces natalensis). The most common method of transmission is by consuming or inhaling rat urine or feces. It can also be spread through cuts and open sores. Person-to-person contact is possible via blood, tissue, secretions.
Symptoms of Lassa fever include bleeding in the gums, nose, difficulty in breathing, cough, vomiting and diarrhea, hepatitis, swollen face, hearing loss, high or low blood pressure, tremors and other CNS conditions.
Read more about Lassa Fever Pipeline Insight here: https://www.globalinsightservices.com/reports/lassa-fever-drug-pipeline-landscape/
Diagnostic tests for Lassa fever are laboratory-based. Lassa fever is diagnosed by using enzyme-linked immunosorbent serologic assays (ELISA). These detect IgM and IgG antibodies and Lassa antigens. Reverse transcription-polymerase chain reaction (RT-PCR) can also be used in the early stages of the disease. Immunohistochemistry stains performed on tissue specimens can be used to make a post-mortem diagnosis.
Rehydration and treatment of symptoms can improve the of survival if there is an early diagnosis. Intravenous ribavirin given early in the course of illness is an effective treatment, in addition to support of fluid and electrolytes, oxygenation, and blood pressure.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Lassa Fever treatment such as EBS-Lassa, GEO-LM01, Lassa Fever Vaccine and others. Key players involved in the development of therapies to treat Lassa Fever are Curevac AG, Emergent BioSolutions Inc, GeoVax Labs Inc, Medigen Inc, Zalgen Labs LLC and others. One drug is under clinical-stage Phase I clinical trials and four drugs are in preclinical and some other drugs are under discovery stages of development.
For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31234
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lassa Fever - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Inovio Pharmaceuticals, Emergent BioSolutions Inc, GeoVax Labs Inc, Globavir Bioscie here
News-ID: 2942781 • Views: …
More Releases from Global Insight Services
Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing …
The Immuno Oncology Drugs Market is rapidly emerging as a transformative segment in the global healthcare industry. These drugs harness the body's immune system to identify and attack cancer cells, offering innovative treatment alternatives to traditional chemotherapy and radiation therapies. Immuno-oncology therapies include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and cell-based therapies such as CAR-T cells. The growth of this market is primarily driven by advancements in biotechnology, an improved…
GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Ove …
The GLP 1 Market is experiencing unprecedented growth, fueled by the rising prevalence of type 2 diabetes and obesity globally. GLP-1, or glucagon-like peptide-1 receptor agonists, represents a groundbreaking therapeutic class that improves insulin secretion, reduces glucagon production, and slows gastric emptying. These mechanisms not only enhance glycemic control but also support weight management, making GLP-1 therapies a preferred choice among healthcare providers and patients alike. Over the years, the…
Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAG …
Market Overview
Autonomous Bus Market is revolutionizing the future of urban mobility through advanced automation technologies. Valued at $2.1 billion in 2024, the market is projected to reach $11.6 billion by 2034, expanding at a strong CAGR of 18.8%. This market focuses on the development and deployment of self-driving buses equipped with cutting-edge sensors, artificial intelligence, and vehicle-to-everything (V2X) communication systems. These buses are designed to improve road safety, enhance passenger…
Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | …
Market Overview
Automotive Tire Market is experiencing remarkable growth as the industry embraces innovation, sustainability, and digital transformation. Valued at $406 billion in 2024, the market is projected to soar to $976.7 billion by 2034, reflecting a CAGR of 9.2%. This expansion is primarily driven by the surge in global vehicle production, growing consumer preference for durable and high-performance tires, and the increasing adoption of smart tire technologies. The Automotive Tire…
More Releases for Lassa
Lassa Fever Market Insights Highlight Expanding Outlook Till 2034, DelveInsight …
The Lassa Fever market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lassa Fever pipeline products will significantly revolutionize the Lassa Fever market dynamics.
DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lassa Fever, historical and forecasted epidemiology as well as the Lassa Fever market trends in the United…
Lassa fever market is expected to reach USD 210 million by 2034
Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, an arenavirus endemic to West Africa. It spreads primarily through contact with food or household items contaminated by rodents (Mastomys natalensis) or through person-to-person transmission in healthcare settings. With an estimated 100,000-300,000 infections annually and ~5,000 deaths, Lassa fever poses a serious public health threat.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71747
Currently, there is no approved…
Lassa Fever Treatment Market, Unraveling Innovations and Strategic Solutions for …
Overview of the Lassa Fever Treatment Market
The global Lassa fever treatment market has been rapidly gaining traction as the prevalence of this viral disease continues to impact public health worldwide. Lassa fever is an acute viral hemorrhagic disease caused by the Lassa virus, primarily transmitted by rodents, particularly the Mastomys species, which are found in parts of West Africa. While Lassa fever has a relatively low mortality rate compared to…
Lassa Fever Market Size, Analysis, Industry Statistics and Latest Insights Till …
Market Overview:
The lassa fever market is expected to exhibit a CAGR of 3.84% during 2023-2033. The lassa fever market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Lassa Fever Treatment Market Trends, Growth Development, Key Opportunity, Applic …
When building an excellent Lassa Fever Treatment Market report, myriad of objectives of the marketing research have been kept in mind. All the data and statistics included in this report is derived from the reliable sources only e.g. journals or white papers of companies etc. This market research report contains several parameters which are thoroughly studied by the experts. This market analysis report provides with a thorough analysis of market…
Lassa Fever Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lassa Fever Market , historical and forecasted epidemiology as well as the Lassa Fever Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Lassa Fever Market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Lassa Fever…
